Research Roundup

Debbie Rigby rounds up the latest in research news

SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials

Both DAPA-HF (assessing dapagliflozin) and EMPEROR-Reduced (assessing empagliflozin) trials showed that sodium-glucose co-transporter-2 (SGLT2) inhibition reduced the combined risk of cardiovascular death or hospitalisation for heart failure in patients with heart failure with reduced ejection fraction (HFrEF) with or without diabetes. Pooled treatment effects show a 13% reduction in all-cause death, 14% reduction in CV death, 26% reduction first hospitalisation for heart failure and 25% decrease in recurrent hospitalisations for heart failure or cardiovascular death.

Lancet, published August 30, 2020.

Medscape commentary


Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation

In a randomized, controlled trial of 331 patients undergoing TAVI who did not have an indication for oral anticoagulation, the incidence of bleeding and the composite of bleeding or thromboembolic events at 1 year were significantly less frequent with aspirin than with aspirin plus clopidogrel administered for 3 months. A bleeding event occurred in 50 patients (15.1%) receiving aspirin alone and in 89 (26.6%) receiving aspirin plus clopidogrel.

New Engl J Med, published 30 August 2020.


Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

The double-blind EMPEROR-Reduced trial of 3730 patients with heart failure and reduced ejection fraction has shown a 25% lower risk of cardiovascular death or hospitalization for heart failure for patients taking empagliflozin (10mg once daily) than those in the placebo group, regardless of the presence or absence of diabetes. The annual rate of decline in the estimated glomerular filtration rate was slower in the empagliflozin group than in the placebo group and empagliflozin-treated patients had a lower risk of serious renal outcomes.

New Engl J Med, published 29 August 2020.

Medscape commentary


Colchicine in Patients with Chronic Coronary Disease

In a randomized trial involving patients with chronic coronary disease, the risk of cardiovascular events was significantly lower (2.5 vs 3.6 events per 100 person-years) among those who received 0.5 mg of colchicine once daily than among those who received placebo. The dose of colchicine was 0.5 mg once daily.

New Engl J Med, published 31 August 2020.


Previous Outgoing president lauded
Next Clinical tips: worms

NOTICE: It can sometimes take awhile for comment submissions to go through, please be patient.

No Comment

Leave a reply